128 related articles for article (PubMed ID: 16755146)
1. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.
Aizawa K; Hanaoka T; Kasai H; Kogashi K; Kumazaki S; Koyama J; Tsutsui H; Yazaki Y; Watanabe N; Kinoshita O; Ikeda U
Hypertens Res; 2006 Feb; 29(2):123-8. PubMed ID: 16755146
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
3. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
5. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
Jing ZC; Jiang X; Wu BX; Xu XQ; Wu Y; Ma CR; Wang Y; Yang YJ; Pu JL; Gao W
Heart; 2009 Sep; 95(18):1531-6. PubMed ID: 19549620
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of vardenafil in difficult-to-treat erectile dysfunction men].
Wang CH
Zhonghua Nan Ke Xue; 2006 Apr; 12(4):377-80. PubMed ID: 16683577
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
Lim ZS; Salmon AP; Vettukattil JJ; Veldtman GR
Int J Cardiol; 2007 May; 118(2):178-82. PubMed ID: 17027100
[TBL] [Abstract][Full Text] [Related]
8. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of vardenafil in the treatment of erectile dysfunction in men with hypertension].
Li HJ
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):953-6. PubMed ID: 17121032
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?
Chapman TH; Wilde M; Sheth A; Madden BP
Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.
Chau EM; Fan KY; Chow WH
Int J Cardiol; 2007 Sep; 120(3):301-5. PubMed ID: 17174418
[TBL] [Abstract][Full Text] [Related]
12. [Phosphodiesterase inhibitors: effectiveness and new applications].
van Driel MF
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data.
Shabsigh R; Duval S; Shah M; Regan TS; Juhasz M; Veltry LG
Curr Med Res Opin; 2007 Oct; 23(10):2453-60. PubMed ID: 17727740
[TBL] [Abstract][Full Text] [Related]
15. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
Madden BP; Sheth A; Wilde M; Ong YE
Vascul Pharmacol; 2007; 47(2-3):184-8. PubMed ID: 17627899
[TBL] [Abstract][Full Text] [Related]
16. Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.
Brisson TE; Broderick GA; Thiel DD; Heckman MG; Pinkstaff DM
Urology; 2006 Aug; 68(2):397-401. PubMed ID: 16904460
[TBL] [Abstract][Full Text] [Related]
17. One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension.
Samarzija M; Zuljević E; Jakopović M; Sever B; Knezević A; Dumija Z; Vidjak V; Samija M
Coll Antropol; 2009 Sep; 33(3):799-803. PubMed ID: 19860106
[TBL] [Abstract][Full Text] [Related]
18. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
Jing ZC; Yu ZX; Shen JY; Wu BX; Xu KF; Zhu XY; Pan L; Zhang ZL; Liu XQ; Zhang YS; Jiang X; Galiè N;
Am J Respir Crit Care Med; 2011 Jun; 183(12):1723-9. PubMed ID: 21471085
[TBL] [Abstract][Full Text] [Related]
19. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Fan YF; Zhang R; Jiang X; Wen L; Wu DC; Liu D; Yuan P; Wang YL; Jing ZC
Cardiovasc Res; 2013 Aug; 99(3):395-403. PubMed ID: 23650288
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
